Brother Enterprises (SZ:002562) Sou Hu Cai Jing·2025-10-27 23:15Core Points - The company held its 19th meeting of the 6th Board of Directors on October 27, 2025, where several resolutions were passed regarding the management and utilization of raised funds [2][3][5]. Group 1: Fund Management and Utilization - The company approved the establishment of a special account for raised funds and signed a tripartite/four-party supervision agreement for fund storage [3]. - The company decided to adjust the actual investment amount of raised funds for specific projects in 2023 [4]. - The company will use part of the idle raised funds for cash management, with a limit of up to 200 million yuan [38]. Group 2: Fund Allocation to Subsidiaries - The company approved the use of raised funds to increase capital or provide loans to its wholly-owned subsidiary, Jiangxi Brother Pharmaceutical Co., Ltd., for project implementation [10][11]. - The total amount allocated for this purpose is 42,824.88 million yuan, which includes net interest income and financial gains [11][12]. Group 3: Fund Replacement and Reimbursement - The company will replace pre-invested self-raised funds and paid issuance expenses with raised funds, totaling 222,647,327.66 yuan [20][21]. - The company will ensure that the replacement of funds does not affect the normal implementation of the investment projects [22][23]. Group 4: Project Timeline and Adjustments - The company announced a delay in the project timeline for the "Annual Production of 600 Tons of Iodinated Contrast Agent Construction Project" to September 2026 [56][57]. - This delay is due to the later-than-expected arrival of raised funds, which has slowed the investment progress [57].